Quarterly UpdatesJul 30, 2026, 08:33 AM
Disc Medicine Advances Pipeline, Q2 Net Loss $59.5M; $718M Cash
AI Summary
Disc Medicine reported significant pipeline advancements and Q2 2026 financial results. The company completed an FDA meeting for bitopertin's Phase 3 APOLLO study, with topline data expected in Q4 2026, and launched an Expanded Access Program. Positive Phase 2 data for selcodebart in myelofibrosis anemia were presented, showing a 56% major anemia response rate. Enrollment for DISC-3405's RESTORE-PV Phase 2 study was completed, with initial data anticipated in Q3 2026. The company maintains a strong financial position with $717.7 million in cash, providing a runway into 2029, despite a Q2 net loss of $59.5 million.
Key Highlights
- Completed FDA Type A meeting for bitopertin, APOLLO Phase 3 data expected Q4 2026.
- Launched Expanded Access Program for bitopertin for eligible EPP patients.
- Selcodebart RALLY-MF Phase 2 showed 56% major anemia response in myelofibrosis.
- Completed enrollment for DISC-3405 RESTORE-PV Phase 2, data expected Q3 2026.
- Ended Q2 2026 with $717.7 million in cash, cash equivalents, and marketable securities.
- Cash runway extended into 2029.
- Reported Q2 2026 net loss of $59.5 million.
- R&D expenses were $46.9 million for Q2 2026.
Price Impact
More from IRON